Business
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development program designed to support registration and global regulatory authorizations for SGT-003 - - Solid received a positive opinion from the European Medicines Agency (EMA) on its Pediatric Investigation Plan (PIP) for SGT-003, establishing alignment on a pediatric clinical development framework in Europe - - 46 participants have been dosed with SGT-003 in
About this update from Solid Biosciences Inc.
[{"type":"image","alt":"Solid Biosciences Inc.","displaySize":"","headline":null,"caption":"Solid Biosciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":169,"url":"https://media.zenfs.com/en/globenewswire.com/5e97e2fffdb55638e3c89b04065944ef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CN5B_bFXVU.yT4eUnV8MYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNw--/https://media.zenfs.com/en/globenewswire.com/5e97e2fffdb55638e3c89b04065944ef","width":300,"height":169},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/CN5B_bFXVU.yT4eUnV8MYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNw--/https://media.zenfs.com/en/globenewswire.com/5e97e2fffdb55638e3c89b04065944ef","width":300,"height":169}},"lazy":false},{"type":"text","content":"- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid’s integrated, multi-trial development program designed to support registration and global regulatory authorizations for SGT-003 -","length":237,"tagName":"p"},{"type":"text","content":"- Solid received a positive opinion from the European Medicines Agency (EMA) on its Pediatric Investigation Plan (PIP) for SGT-003, establishing alignment on a pediatric clinical development framework in Europe -","length":212,"tagName":"p"},{"type":"text","content":"- 46 participants have been dosed with SGT-003 in the Phase 1/2 INSPIRE DUCHENNE clinical trial using a steroid-only prophylactic immunomodulation regimen; SGT-003 has been generally well tolerated as of a May 4, 2026, cutoff date -","length":232,"tagName":"p"},{"type":"text","content":"CHARLESTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the first participant has been dosed in IMPACT DUCHENNE, the Company’s multi-country, placebo-controlled, randomized, double-blind, Phase 3 clinical trial investigating SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne).","length":480,"tagName":"p"},{"type":"text","content":"IMPACT DUCHENNE and the ongoing Phase 1/2 INSPIRE DUCHENNE clinical trials are components of an integrated, multi-trial clinical development program designed to evaluate the safety and efficacy of a single intravenous dose of SGT-00...